404 related articles for article (PubMed ID: 32217372)
1. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
[TBL] [Abstract][Full Text] [Related]
2. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
Kimura H; Sampei S; Matsuoka D; Harada N; Watanabe H; Arimitsu K; Ono M; Saji H
Bioorg Med Chem; 2016 May; 24(10):2251-6. PubMed ID: 27073053
[TBL] [Abstract][Full Text] [Related]
3. Clinical translation of a PSMA inhibitor for
Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Radiolabeling of Glu-Urea-Lys with
Hatamabadi D; Joukar S; Shakeri P; Balalaie S; Yazdani A; Khoramjouy M; Mazidi SM; Kobarfard F; Mosayebnia M; Bozorgchami N; Ahmadi M; Ayyoubzadeh SM; Shahhosseini S
Cancer Biother Radiopharm; 2023 Sep; 38(7):486-496. PubMed ID: 37578479
[No Abstract] [Full Text] [Related]
5.
Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
[TBL] [Abstract][Full Text] [Related]
6. Preparation and Biological Evaluation of [
Xiao D; Duan X; Gan Q; Zhang X; Zhang J
Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Evaluation of
Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of a Novel High-Affinity Radioligand [
Bezverkhniaia E; Kanellopoulos P; Abouzayed A; Larkina M; Oroujeni M; Vorobyeva A; Rosenström U; Tolmachev V; Orlova A
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139219
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
13. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG
J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782
[TBL] [Abstract][Full Text] [Related]
14. Preparation of
Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
[TBL] [Abstract][Full Text] [Related]
15. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a New
Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Radiation dosimetry of
Zhang J; Zhang J; Xu X; Lu L; Hu S; Liu C; Cheng J; Song S; Zhang Y; Shi LQ
Sci Rep; 2020 Mar; 10(1):4179. PubMed ID: 32144340
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
19. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
[TBL] [Abstract][Full Text] [Related]
20. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
